Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland E Schmieder

Showing results (1-10 of 505) with videos related to

Pageof 51
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 17, 2020
Renal denervation: where do we stand and what is the relevance to the nephrologist?Roland E Schmieder
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|May 31, 2015
Managing Treatment-Resistant PatientsRoland E Schmieder
Clinical Kidney Journal|December 15, 2025
2025 Update on resistant hypertension in CKD: where do we stand and where do we go?Roland E Schmieder
Expert Opinion on Pharmacotherapy|October 27, 2004
Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertensionRoland E Schmieder
Current Hypertension Reports|January 8, 2008
Renin inhibitors: optimal strategy for renal protectionRoland E Schmieder
American Journal of Hypertension|February 16, 2010
Angiotensin II-type 2 receptor: emerging target for cardiovascular protectionRoland E Schmieder
Nature Reviews. Cardiology|October 1, 2014
Renal denervation--a valid treatment option despite SYMPLICITY HTN-3Roland E Schmieder
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 26, 2022
Renal denervation in patients with chronic kidney disease: current evidence and future perspectivesRoland E Schmieder
American Journal of Hypertension|May 11, 2005
Mechanisms for the clinical benefits of angiotensin II receptor blockersRoland E Schmieder
Journal of Hypertension|April 19, 2005
Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockersRoland E Schmieder
Pageof 51

Showing results (1-10 of 505) with videos related to

Sort By:
Pageof 51
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 17, 2020
Renal denervation: where do we stand and what is the relevance to the nephrologist?Roland E Schmieder
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|May 31, 2015
Managing Treatment-Resistant PatientsRoland E Schmieder
Clinical Kidney Journal|December 15, 2025
2025 Update on resistant hypertension in CKD: where do we stand and where do we go?Roland E Schmieder
Expert Opinion on Pharmacotherapy|October 27, 2004
Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertensionRoland E Schmieder
Current Hypertension Reports|January 8, 2008
Renin inhibitors: optimal strategy for renal protectionRoland E Schmieder
American Journal of Hypertension|February 16, 2010
Angiotensin II-type 2 receptor: emerging target for cardiovascular protectionRoland E Schmieder
Nature Reviews. Cardiology|October 1, 2014
Renal denervation--a valid treatment option despite SYMPLICITY HTN-3Roland E Schmieder
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 26, 2022
Renal denervation in patients with chronic kidney disease: current evidence and future perspectivesRoland E Schmieder
American Journal of Hypertension|May 11, 2005
Mechanisms for the clinical benefits of angiotensin II receptor blockersRoland E Schmieder
Journal of Hypertension|April 19, 2005
Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockersRoland E Schmieder
Pageof 51